The data was presented by Dr Wieselthaler, cardiothoracic surgeon at Vienna General Hospital, at the annual meeting of the International Society for Heart and Lung Transplantation held in Boston.
The results showed a six-month survival rate of 91 per cent among the first 23 patients implanted with the HeartWare device.
Of the 23 patients, 21 patients met the primary endpoint of the trial, defined as survival to 180 days or transplantation. These included 19 patients who were supported by the HeartWare system at 180 days and 2 patients who received transplants, after 157 days and 176 days respectively.
Dr. Wieselthaler noted that one of the key features of the pump is its small size, which allows it to be implanted in the chest, thereby avoiding the abdominal surgery generally required to implant competing devices.
rweabn.com.au
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
|
|
